These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

199 related items for PubMed ID: 21493074

  • 21. Antiviral potential of a new generation of acyclic nucleoside phosphonates, the 6-[2-(phosphonomethoxy)alkoxy]-2,4-diaminopyrimidines.
    De Clercq E, Andrei G, Balzarini J, Leyssen P, Naesens L, Neyts J, Pannecouque C, Snoeck R, Ying C, Hocková D, Holý A.
    Nucleosides Nucleotides Nucleic Acids; 2005; 24(5-7):331-41. PubMed ID: 16247948
    [Abstract] [Full Text] [Related]

  • 22. Alkoxyalkyl esters of cidofovir and cyclic cidofovir exhibit multiple-log enhancement of antiviral activity against cytomegalovirus and herpesvirus replication in vitro.
    Beadle JR, Hartline C, Aldern KA, Rodriguez N, Harden E, Kern ER, Hostetler KY.
    Antimicrob Agents Chemother; 2002 Aug; 46(8):2381-6. PubMed ID: 12121908
    [Abstract] [Full Text] [Related]

  • 23. Ether lipid-ester prodrugs of acyclic nucleoside phosphonates: activity against adenovirus replication in vitro.
    Hartline CB, Gustin KM, Wan WB, Ciesla SL, Beadle JR, Hostetler KY, Kern ER.
    J Infect Dis; 2005 Feb 01; 191(3):396-9. PubMed ID: 15633099
    [Abstract] [Full Text] [Related]

  • 24. Enhanced antiproliferative effects of alkoxyalkyl esters of cidofovir in human cervical cancer cells in vitro.
    Hostetler KY, Rought S, Aldern KA, Trahan J, Beadle JR, Corbeil J.
    Mol Cancer Ther; 2006 Jan 01; 5(1):156-9. PubMed ID: 16432174
    [Abstract] [Full Text] [Related]

  • 25. Esterification of cidofovir with alkoxyalkanols increases oral bioavailability and diminishes drug accumulation in kidney.
    Ciesla SL, Trahan J, Wan WB, Beadle JR, Aldern KA, Painter GR, Hostetler KY.
    Antiviral Res; 2003 Aug 01; 59(3):163-71. PubMed ID: 12927306
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Effect of oral treatment with hexadecyloxypropyl-[(S)-9-(3-hydroxy-2- phosphonylmethoxypropyl)adenine] [(S)-HPMPA] or octadecyloxyethyl-(S)-HPMPA on cowpox or vaccinia virus infections in mice.
    Quenelle DC, Collins DJ, Herrod BP, Keith KA, Trahan J, Beadle JR, Hostetler KY, Kern ER.
    Antimicrob Agents Chemother; 2007 Nov 01; 51(11):3940-7. PubMed ID: 17846137
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Efficacy of multiple- or single-dose cidofovir against vaccinia and cowpox virus infections in mice.
    Quenelle DC, Collins DJ, Kern ER.
    Antimicrob Agents Chemother; 2003 Oct 01; 47(10):3275-80. PubMed ID: 14506041
    [Abstract] [Full Text] [Related]

  • 30. Mutations in the E9L polymerase gene of cidofovir-resistant vaccinia virus strain WR are associated with the drug resistance phenotype.
    Kornbluth RS, Smee DF, Sidwell RW, Snarsky V, Evans DH, Hostetler KY.
    Antimicrob Agents Chemother; 2006 Dec 01; 50(12):4038-43. PubMed ID: 16982794
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Micelle formulation of hexadecyloxypropyl-cidofovir (HDP-CDV) as an intravitreal long-lasting delivery system.
    Ma F, Nan K, Lee S, Beadle JR, Hou H, Freeman WR, Hostetler KY, Cheng L.
    Eur J Pharm Biopharm; 2015 Jan 01; 89():271-9. PubMed ID: 25513956
    [Abstract] [Full Text] [Related]

  • 33.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 34. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses.
    Smee DF, Sidwell RW, Kefauver D, Bray M, Huggins JW.
    Antimicrob Agents Chemother; 2002 May 01; 46(5):1329-35. PubMed ID: 11959564
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Effect of oral treatment with (S)-HPMPA, HDP-(S)-HPMPA or ODE-(S)-HPMPA on replication of murine cytomegalovirus (MCMV) or human cytomegalovirus (HCMV) in animal models.
    Quenelle DC, Collins DJ, Pettway LR, Hartline CB, Beadle JR, Wan WB, Hostetler KY, Kern ER.
    Antiviral Res; 2008 Aug 01; 79(2):133-5. PubMed ID: 18336926
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Solution structure of a DNA duplex containing the potent anti-poxvirus agent cidofovir.
    Julien O, Beadle JR, Magee WC, Chatterjee S, Hostetler KY, Evans DH, Sykes BD.
    J Am Chem Soc; 2011 Feb 23; 133(7):2264-74. PubMed ID: 21280608
    [Abstract] [Full Text] [Related]

  • 39. Cutaneous infections of mice with vaccinia or cowpox viruses and efficacy of cidofovir.
    Quenelle DC, Collins DJ, Kern ER.
    Antiviral Res; 2004 Jul 23; 63(1):33-40. PubMed ID: 15196818
    [Abstract] [Full Text] [Related]

  • 40. Oral hexadecyloxypropyl-cidofovir therapy in pregnant guinea pigs improves outcome in the congenital model of cytomegalovirus infection.
    Bravo FJ, Bernstein DI, Beadle JR, Hostetler KY, Cardin RD.
    Antimicrob Agents Chemother; 2011 Jan 23; 55(1):35-41. PubMed ID: 21078944
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.